Growth Opportunities in Gene Therapy to Transform Short Bowel Syndrome Treatment
Short Bowel Syndrome Market The Short Bowel Syndrome Market is estimated to be valued at US$ 188.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Short bowel syndrome is a malabsorptive disorder that occurs when the small intestine does not absorb enough nutrients and water from food. It is a condition usually caused by surgical removal of part of the small intestine, resulting in problems with digestion and absorption of nutrients. SBS patients require parenteral nutrition support for survival. Market Dynamics: The short bowel syndrome market is primarily driven by two key factors: High cost of immunotherapy treatment: Immunotherapy drugs used for treating short bowel syndrome come with a heavy price tag which limits their widespread adoption. For instance, Teduglutide costs over $300,000 annually per patient in the US. This high cost...